Zhang Yunyuan, Lun Limin, Zhu Baozhi, Wang Qing, Ding Chunming, Hu Yanlin, Huang Weili, Zhou Lan, Chen Xian, Huang Hai
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.
Department of Orthopedic Surgery, Qingdao Municipal Hospital, Qingdao, 266011, People's Republic of China.
J Orthop Surg Res. 2016 Nov 3;11(1):133. doi: 10.1186/s13018-016-0470-2.
Recently, more and more evidences have revealed the association between CD44V6 and osteosarcoma (OS), but whether it can be used as a clinical biomarker is still unknown. The purpose of this study is to assess the diagnostic value of CD44V6 in OS by conducting a meta-analysis.
All relevant electronic literatures were collected from seven international databases together with three Chinese databases up to April 23, 2016. Eligible studies were selected through multiple search strategies and the quality was assessed by QUADAS. Data was extracted from studies according to the key statistics index. All analyses were performed using STATA 12 and Meta-DiSc 1.4 statistical software.
According to the exclusion and inclusion criteria, 8 literatures were retrieved, accounting for 463 cases and 188 controls. For discriminating OS from benign bone tumor or healthy controls, the area under the receiver operating characteristic curve (AUC) was 0.91 (95 % CI 0.88-0.93). Overall, the results showed pooled sensitivity of 0.743 (95 % CI 0.606-0.844) and specificity of 0.897 (95 % CI 0.818-0.945), respectively. Substantial heterogeneity was detected in this study (I = 90 %). The publication bias was assessed by using Deeks' asymmetry test (p = 0.795). No evidence of heterogeneity from threshold effects was detected by the Spearman correlation coefficient (-0.506, p = 0.201). Meta-regression was performed to mining the source of heterogeneity, and subgroup analysis showed that neither the cut-off values nor the control groups were the source of heterogeneity.
The present results suggest that promoted CD44V6 expression levels are associated with OS and CD44V6 may be used as a diagnostic marker for OS.
最近，越来越多的证据揭示了CD44V6与骨肉瘤（OS）之间的关联，但它是否可作为临床生物标志物仍不清楚。本研究的目的是通过进行荟萃分析来评估CD44V6在骨肉瘤中的诊断价值。
截至2016年4月23日，从七个国际数据库和三个中文数据库中收集所有相关电子文献。通过多种检索策略选择符合条件的研究，并采用QUADAS评估质量。根据关键统计指标从研究中提取数据。所有分析均使用STATA 12和Meta-DiSc 1.4统计软件进行。
根据排除和纳入标准，检索到8篇文献，共463例病例和188例对照。用于区分骨肉瘤与良性骨肿瘤或健康对照时，受试者工作特征曲线（AUC）下的面积为0.91（95%可信区间0.88-0.93）。总体而言，结果显示合并敏感度为0.743（95%可信区间0.606-0.844），特异度为0.897（95%可信区间0.818-0.945）。本研究检测到显著异质性（I² = 90%）。采用Deeks不对称检验评估发表偏倚（p = 0.795）。Spearman相关系数未检测到阈值效应导致异质性的证据（-0.506，p = 0.201）。进行Meta回归以挖掘异质性来源，亚组分析表明截断值和对照组均不是异质性来源。
目前结果表明，CD44V6表达水平升高与骨肉瘤相关，且CD44V6可能用作骨肉瘤的诊断标志物。
